February 24, 2023
LexaGene announces that it has ceased operations.
February 10, 2023
LexaGene announces the results of its annual general meeting held on February 8, 2023 (the “AGM”).
February 8, 2023
LexaGene provides an update on the Company’s efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics.
January 18, 2023
LexaGene announces exciting news regarding the ability of the MiQLab System to detect Mycoplasma at minute levels.
December 16, 2022
LexaGene announces that the large biopharma company that previously purchased a MiQLab System has engaged LexaGene in a second statement of work (“SOW”) that builds off of the previously completed SOW.
December 7, 2022
LexaGene announces that it intends to amend the exercise price of certain common share purchase warrants.
November 22, 2022
LexaGene announces the completion of a validation study with a major biopharma company that recently purchased a MiQLab System for the possible use of the technology in its manufacturing processes.
November 1, 2022
LexaGene announces that it it has issued a 12% secured convertible note (the “Note”) to Meridian LGH Holdings 2, LLC.
October 27, 2022
LexaGene announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on October 29, 2019.
October 20, 2022
LexaGene announces that it has signed a statement of work with the same biopharma company that purchased a System last week.
For Marketing inquiries, please email:
info@lexagene.com
800-215-1824